Comparative Pharmacology
Head-to-head clinical analysis: HAILEY FE 1 20 versus NORINYL 1 50 28 DAY.
Head-to-head clinical analysis: HAILEY FE 1 20 versus NORINYL 1 50 28 DAY.
HAILEY FE 1/20 vs NORINYL 1+50 28-DAY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive containing ethinyl estradiol and norethindrone. Suppresses gonadotropin (FSH and LH) release via negative feedback on the hypothalamic-pituitary-ovarian axis, inhibiting ovulation. Also alters cervical mucus and endometrial lining to impair sperm penetration and implantation.
Norethindrone and ethinyl estradiol combination works by suppressing gonadotropin-releasing hormone (GnRH) from the hypothalamus, reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion, thereby inhibiting ovulation. Norethindrone also alters cervical mucus viscosity and endometrial lining, impeding sperm penetration and implantation.
One tablet orally once daily for 21 consecutive days followed by 7 days of placebo tablets.
One tablet orally once daily for 28 days, with 7 inactive tablets during the last 7 days. Each active tablet contains norethindrone 1 mg and ethinyl estradiol 50 mcg.
None Documented
None Documented
Ethinyl estradiol: approximately 17 ± 5 hours (terminal); Norethindrone: approximately 8 ± 2 hours (terminal). Clinical context: Steady-state reached within 7-10 days; once-daily dosing maintains effective concentrations for contraceptive efficacy.
Norethindrone: ~8-11 hours; Mestranol: 24 hours (prodrug, ethinyl estradiol half-life ~13-27 hours).
Renal (approximately 50-60% as metabolites, including glucuronide conjugates of ethinyl estradiol and norethindrone, and about 20% as unchanged norethindrone); Fecal (approximately 30-40% as metabolites); Biliary (minor, with enterohepatic circulation of ethinyl estradiol conjugates).
Renal: ~40% as metabolites; Biliary/Fecal: ~60% as metabolites.
Category C
Category C
Oral Contraceptive
Oral Contraceptive